Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism

TY - JOUR

T1 - Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism

AU - Sönmezer, M.

AU - Özmen, B.

AU - Atabekoglu, C. S.

AU - Papuccu, E. G.

AU - Ozkavukcu, S.

AU - Berker, B.

AU - Pabuccu, R.

PY - 2012/7

Y1 - 2012/7

N2 - Purpose The role of serum AMH levels in prediction of ovarian response in idiopathic hypogonadotropic hypogonadism (IHH) was evaluated. Material method(s) Twelve patients with IHH underwent controlled ovarian hyperstimulation (COH) for IVF were enrolled in this prospective study. Serum AMH levels were studied on the 2nd or 3rd day of an induced menstrual cycle by a preceding low-dose oral contraceptive pill treatment. A fixed dose (150-300 IU/day) of hMG was given in all COH cycles. Correlations between serum AMH levels, COH outcomes and embryological data were investigated. Results Mean serum AMH levels was 3.47±2.15 ng/mL and mean serum peak estradiol was 2196±1705 pg/mL. Mean number of follicles >14 mm, >17 mm on hCG day and MII oocytes were 4.14±3.2, 4±2.5 and 7.28±3.5, respectively. Mean number of grade A embryos and transferred embryos were 3.28±2.4 and 2.5±0.7, respectively. The clinical pregnancy rate per patient was 41.6 % (5/12). Positive correlations were observed between serum AMH levels and MII oocytes (r00.84), grade A embryos (r00.85), serum peak estradiol levels (r00.87), and number of follicles >14 mm (r00.83) and >17 mm (r00.81) on hCG day, respectively. Conclusion AMH appears as a promising marker of ovarian response in patients with IHH undergoing IVF.

AB - Purpose The role of serum AMH levels in prediction of ovarian response in idiopathic hypogonadotropic hypogonadism (IHH) was evaluated. Material method(s) Twelve patients with IHH underwent controlled ovarian hyperstimulation (COH) for IVF were enrolled in this prospective study. Serum AMH levels were studied on the 2nd or 3rd day of an induced menstrual cycle by a preceding low-dose oral contraceptive pill treatment. A fixed dose (150-300 IU/day) of hMG was given in all COH cycles. Correlations between serum AMH levels, COH outcomes and embryological data were investigated. Results Mean serum AMH levels was 3.47±2.15 ng/mL and mean serum peak estradiol was 2196±1705 pg/mL. Mean number of follicles >14 mm, >17 mm on hCG day and MII oocytes were 4.14±3.2, 4±2.5 and 7.28±3.5, respectively. Mean number of grade A embryos and transferred embryos were 3.28±2.4 and 2.5±0.7, respectively. The clinical pregnancy rate per patient was 41.6 % (5/12). Positive correlations were observed between serum AMH levels and MII oocytes (r00.84), grade A embryos (r00.85), serum peak estradiol levels (r00.87), and number of follicles >14 mm (r00.83) and >17 mm (r00.81) on hCG day, respectively. Conclusion AMH appears as a promising marker of ovarian response in patients with IHH undergoing IVF.

KW - Anti-Mullerian hormone

KW - Hypogonadotropic hypogonadism

KW - IVF outcome

KW - Ovarian reserve

KW - Ovarian response

UR - https://www.scopus.com/pages/publications/84864912170

U2 - 10.1007/s10815-012-9759-1

DO - 10.1007/s10815-012-9759-1

M3 - Article

C2 - 22547042

AN - SCOPUS:84864912170

SN - 1058-0468

VL - 29

SP - 597

EP - 602

JO - Journal of Assisted Reproduction and Genetics

JF - Journal of Assisted Reproduction and Genetics

IS - 7

ER -